{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:40:30Z","timestamp":1787020830411,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Several retrospective studies have identified risk factors associated with ocular myasthenia gravis (OMG) generalization in non-surgical patients. However, the outcomes of OMG after thymectomy have not been investigated fully. This study aimed to explore the clinical predictors of post-thymectomy OMG prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective review of OMG patients who underwent thymectomy at our institution from January 2012 to December 2021. Kaplan\u2013Meier and Cox proportional hazard regression analyses were used to evaluate associations between clinical features and prognosis. The main outcome measures were OMG conversion, complete stable remission (CSR), and clinical improvement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fifty-eight patients were identified for conversion analysis. Thirteen (22.4%) developed generalized myasthenia gravis (GMG) at a median time of 12.7 (3\u201337.3) months from symptom onset. Repetitive nerve stimulation (RNS)-positivity was associated with increased risk of conversion to GMG (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.002). Patients with histotype B2\/B3 thymoma showed a higher risk of conversion (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.002) than did patients with hyperplasia and AB\/B1 thymoma. Fifty-two patients fulfilled the criteria for CSR and improvement. Sixteen (30.8%) achieved CSR at a median time of 28.7 (15\u201354) months after thymectomy. Fifteen (28.8%) showed clinical improvement at last follow up. Patients who achieved CSR showed a younger age of onset (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.022), lower percentage of acetylcholine receptor antibody-seropositivity (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.029). Histologically, patients with thymic hyperplasia and stage I thymoma showed a higher chance of CSR (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.010) than did patients with stage II\/III thymoma. Multivariate analysis revealed that RNS-positivity (hazard ratio [HR] 6.007,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.021) and histotype B2\/B3 thymoma (HR 4.611,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.048) were associated with OMG conversion. Thymic hyperplasia and stage I thymoma (HR 0.300,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.026) were associated with OMG CSR after thymectomy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>For OMG patients after thymectomy, RNS-positivity and histotype B2\/B3 thymoma are independent predictors of conversion to GMG. On the other hand, thymic hyperplasia and stage I thymoma independently predict CSR.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-022-02454-y","type":"journal-article","created":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T07:03:34Z","timestamp":1660028614000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Thymectomy in ocular myasthenia gravis\u2014prognosis and risk factors analysis"],"prefix":"10.1186","volume":"17","author":[{"given":"Jinwei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuantao","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9658-4172","authenticated-orcid":false,"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,9]]},"reference":[{"issue":"1","key":"2454_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren J. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30.","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"2454_CR2","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14(10):1023\u201336.","journal-title":"Lancet Neurol"},{"issue":"1","key":"2454_CR3","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s11910-013-0421-9","volume":"14","author":"SH Wong","year":"2014","unstructured":"Wong SH, Huda S, Vincent A, Plant GT. Ocular myasthenia gravis: controversies and updates. Curr Neurol Neurosci Rep. 2014;14(1):421.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"2","key":"2454_CR4","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1159\/000507853","volume":"83","author":"X Feng","year":"2020","unstructured":"Feng X, Huan X, Yan C, Song J, Lu J, Zhou L, et al. Adult ocular myasthenia gravis conversion: a single-center retrospective analysis in China. Eur Neurol. 2020;83(2):182\u20138.","journal-title":"Eur Neurol"},{"issue":"1","key":"2454_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/00207454.2017.1344237","volume":"128","author":"M Mazzoli","year":"2018","unstructured":"Mazzoli M, Ariatti A, Valzania F, Kaleci S, Tondelli M, Nichelli PF, et al. Factors affecting outcome in ocular myasthenia gravis. Int J Neurosci. 2018;128(1):15\u201324.","journal-title":"Int J Neurosci"},{"issue":"3","key":"2454_CR6","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1097\/WNO.0000000000000350","volume":"36","author":"SH Wong","year":"2016","unstructured":"Wong SH, Petrie A, Plant GT. Ocular myasthenia gravis: toward a risk of generalization score and sample size calculation for a randomized controlled trial of disease modification. J Neuroophthalmol. 2016;36(3):252\u20138.","journal-title":"J Neuroophthalmol"},{"issue":"2","key":"2454_CR7","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/JTO.0000000000000393","volume":"10","author":"CA Weis","year":"2015","unstructured":"Weis CA, Yao X, Deng Y, Detterbeck FC, Marino M, Nicholson AG, et al. The impact of thymoma histotype on prognosis in a worldwide database. J Thorac Oncol. 2015;10(2):367\u201372.","journal-title":"J Thorac Oncol"},{"issue":"Suppl 15","key":"2454_CR8","doi-asserted-by":"publisher","first-page":"S2005","DOI":"10.21037\/jtd.2019.06.40","volume":"11","author":"A Amini","year":"2019","unstructured":"Amini A, Rusthoven CG. Thymoma: does tumor size matter? J Thorac Dis. 2019;11(Suppl 15):S2005\u20137.","journal-title":"J Thorac Dis"},{"issue":"4","key":"2454_CR9","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3988\/jcn.2015.11.4.372","volume":"11","author":"SH Kim","year":"2015","unstructured":"Kim SH, Koh IS, Minn YK. Pathologic finding of thymic carcinoma accompanied by myasthenia gravis. J Clin Neurol. 2015;11(4):372\u20135.","journal-title":"J Clin Neurol"},{"issue":"10","key":"2454_CR10","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1097\/JTO.0000000000000654","volume":"10","author":"A Marx","year":"2015","unstructured":"Marx A, Chan JK, Coindre JM, Detterbeck F, Girard N, Harris NL, et al. The 2015 world health organization classification of tumors of the thymus: continuity and changes. J Thorac Oncol. 2015;10(10):1383\u201395.","journal-title":"J Thorac Oncol"},{"issue":"7 Suppl 3","key":"2454_CR11","doi-asserted-by":"publisher","first-page":"S1710","DOI":"10.1097\/JTO.0b013e31821e8cff","volume":"6","author":"FC Detterbeck","year":"2011","unstructured":"Detterbeck FC, Nicholson AG, Kondo K, Van Schil P, Moran C. The Masaoka-Koga stage classification for thymic malignancies: clarification and definition of terms. J Thorac Oncol. 2011;6(7 Suppl 3):S1710\u20136.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"2454_CR12","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;96(3):114\u201322.","journal-title":"Neurology"},{"issue":"6","key":"2454_CR13","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1602489","volume":"375","author":"GI Wolfe","year":"2016","unstructured":"Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, et al. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med. 2016;375(6):511\u201322.","journal-title":"N Engl J Med"},{"key":"2454_CR14","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jaut.2013.12.011","volume":"52","author":"S Berrih-Aknin","year":"2014","unstructured":"Berrih-Aknin S, Le Panse R. Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms. J Autoimmun. 2014;52:90\u2013100.","journal-title":"J Autoimmun"},{"issue":"1","key":"2454_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12883-017-0857-7","volume":"17","author":"L Wang","year":"2017","unstructured":"Wang L, Zhang Y, He M. Clinical predictors for the prognosis of myasthenia gravis. BMC Neurol. 2017;17(1):77.","journal-title":"BMC Neurol"},{"issue":"6","key":"2454_CR16","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.athoracsur.2011.08.001","volume":"92","author":"Z Liu","year":"2011","unstructured":"Liu Z, Feng H, Yeung SC, Zheng Z, Liu W, Ma J, et al. Extended transsternal thymectomy for the treatment of ocular myasthenia gravis. Ann Thorac Surg. 2011;92(6):1993\u20139.","journal-title":"Ann Thorac Surg"},{"issue":"10","key":"2454_CR17","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1007\/s10072-017-3058-7","volume":"38","author":"K Zhu","year":"2017","unstructured":"Zhu K, Li J, Huang X, Xu W, Liu W, Chen J, et al. Thymectomy is a beneficial therapy for patients with non-thymomatous ocular myasthenia gravis: a systematic review and meta-analysis. Neurol Sci. 2017;38(10):1753\u201360.","journal-title":"Neurol Sci"},{"issue":"3","key":"2454_CR18","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s13760-018-0943-7","volume":"118","author":"G Galassi","year":"2018","unstructured":"Galassi G, Mazzoli M, Ariatti A, Kaleci S, Valzania F, Nichelli PF. Antibody profile may predict outcome in ocular myasthenia gravis. Acta Neurol Belg. 2018;118(3):435\u201343.","journal-title":"Acta Neurol Belg"},{"issue":"6","key":"2454_CR19","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1001\/jamaneurol.2015.0203","volume":"72","author":"PM Rodr\u00edguez Cruz","year":"2015","unstructured":"Rodr\u00edguez Cruz PM, Al-Hajjar M, Huda S, Jacobson L, Woodhall M, Jayawant S, et al. Clinical features and diagnostic usefulness of antibodies to clustered acetylcholine receptors in the diagnosis of seronegative myasthenia gravis. JAMA Neurol. 2015;72(6):642\u20139.","journal-title":"JAMA Neurol"},{"key":"2454_CR20","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","volume":"52","author":"P Zisimopoulou","year":"2014","unstructured":"Zisimopoulou P, Evangelakou P, Tzartos J, Lazaridis K, Zouvelou V, Mantegazza R, et al. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun. 2014;52:139\u201345.","journal-title":"J Autoimmun"},{"issue":"9","key":"2454_CR21","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1001\/jamaneurol.2016.2032","volume":"73","author":"E Cort\u00e9s-Vicente","year":"2016","unstructured":"Cort\u00e9s-Vicente E, Gallardo E, Mart\u00ednez M, D\u00edaz-Manera J, Querol L, Rojas-Garc\u00eda R, et al. Clinical characteristics of patients with double-seronegative myasthenia gravis and antibodies to cortactin. JAMA Neurol. 2016;73(9):1099\u2013104.","journal-title":"JAMA Neurol"},{"issue":"2","key":"2454_CR22","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jns.2003.08.017","volume":"217","author":"NT Monsul","year":"2004","unstructured":"Monsul NT, Patwa HS, Knorr AM, Lesser RL, Goldstein JM. The effect of prednisone on the progression from ocular to generalized myasthenia gravis. J Neurol Sci. 2004;217(2):131\u20133.","journal-title":"J Neurol Sci"},{"issue":"8","key":"2454_CR23","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1007\/s00415-009-5120-8","volume":"256","author":"MJ Kupersmith","year":"2009","unstructured":"Kupersmith MJ. Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up. J Neurol. 2009;256(8):1314\u201320.","journal-title":"J Neurol"},{"issue":"4","key":"2454_CR24","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/00041327-200312000-00002","volume":"23","author":"J Mee","year":"2003","unstructured":"Mee J, Paine M, Byrne E, King J, Reardon K, O\u2019Day J. Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis. J Neuroophthalmol. 2003;23(4):251\u20135.","journal-title":"J Neuroophthalmol"},{"key":"2454_CR25","first-page":"4458","volume":"3","author":"J Sarkkinen","year":"2022","unstructured":"Sarkkinen J, Dunkel J, Tuulasvaara A, Huuskonen A, Atula S, Kek\u00e4l\u00e4inen E, et al. Ectopic germinal centers in the thymus accurately predict prognosis of myasthenia gravis after thymectomy. Mod Pathol. 2022;3:4458.","journal-title":"Mod Pathol."},{"issue":"1","key":"2454_CR26","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s12883-020-01805-1","volume":"20","author":"J Ding","year":"2020","unstructured":"Ding J, Zhao S, Ren K, Dang D, Li H, Wu F, et al. Prediction of generalization of ocular myasthenia gravis under immunosuppressive therapy in Northwest China. BMC Neurol. 2020;20(1):238.","journal-title":"BMC Neurol"},{"issue":"2","key":"2454_CR27","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3988\/jcn.2021.17.2.265","volume":"17","author":"KH Kim","year":"2021","unstructured":"Kim KH, Kim SW, Shin HY. Initial repetitive nerve stimulation test predicts conversion of ocular myasthenia gravis to generalized myasthenia gravis. J Clin Neurol. 2021;17(2):265\u201372.","journal-title":"J Clin Neurol"},{"key":"2454_CR28","first-page":"7780","volume":"6","author":"A K\u0131sabay","year":"2021","unstructured":"K\u0131sabay A, \u00d6zdemir HN, G\u00f6k\u00e7ay F, \u00c7elebisoy N. Risk for generalization in ocular onset myasthenia gravis: experience from a neuro-ophthalmology clinic. Acta Neurol Belg. 2021;6:7780.","journal-title":"Acta Neurol Belg."},{"issue":"11","key":"2454_CR29","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1111\/1759-7714.13188","volume":"10","author":"D Tian","year":"2019","unstructured":"Tian D, Shiiya H, Sato M, Sun CB, Anraku M, Nakajima J. Tumor location may affect the clinicopathological features and prognosis of thymomas. Thorac Cancer. 2019;10(11):2096\u2013105.","journal-title":"Thorac Cancer"},{"issue":"1","key":"2454_CR30","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1093\/ejcts\/ezz001","volume":"56","author":"M Okumura","year":"2019","unstructured":"Okumura M, Yoshino I, Yano M, Watanabe SI, Tsuboi M, Yoshida K, et al. Tumour size determines both recurrence-free survival and disease-specific survival after surgical treatment for thymoma. Eur J Cardiothorac Surg. 2019;56(1):174\u201381.","journal-title":"Eur J Cardiothorac Surg"},{"issue":"5","key":"2454_CR31","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.jtcvs.2012.12.053","volume":"145","author":"TC Mineo","year":"2013","unstructured":"Mineo TC, Ambrogi V. Outcomes after thymectomy in class I myasthenia gravis. J Thorac Cardiovasc Surg. 2013;145(5):1319\u201324.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"3","key":"2454_CR32","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1067\/mtc.2001.116191","volume":"122","author":"PF Roberts","year":"2001","unstructured":"Roberts PF, Venuta F, Rendina E, De Giacomo T, Coloni GF, Follette DM, et al. Thymectomy in the treatment of ocular myasthenia gravis. J Thorac Cardiovasc Surg. 2001;122(3):562\u20138.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"2","key":"2454_CR33","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/j.1600-0404.2005.00424.x","volume":"112","author":"CS Huang","year":"2005","unstructured":"Huang CS, Hsu HS, Huang BS, Lee HC, Kao KP, Hsu WH, et al. Factors influencing the outcome of transsternal thymectomy for myasthenia gravis. Acta Neurol Scand. 2005;112(2):108\u201314.","journal-title":"Acta Neurol Scand"},{"issue":"3","key":"2454_CR34","doi-asserted-by":"publisher","first-page":"422","DOI":"10.21037\/jtd.2020.01.17","volume":"12","author":"X Liu","year":"2020","unstructured":"Liu X, Zhou W, Hu J, Hu M, Gao W, Zhang S, et al. Prognostic predictors of remission in ocular myasthenia after thymectomy. J Thorac Dis. 2020;12(3):422\u201330.","journal-title":"J Thorac Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02454-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02454-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02454-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T07:20:43Z","timestamp":1660029643000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02454-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,9]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2454"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02454-y","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,9]]},"assertion":[{"value":"7 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of Tianjin Medical University General Hospital (Ethical No. IRB2022-WZ-024) and conducted according to the principles of the Declaration of Helsinki. The need for patient consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and approved the content, and agreed to submit the article in consideration for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing financial interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"309"}}